Welcome to our dedicated page for Xenon Pharmaceuticals news (Ticker: XENE), a resource for investors and traders seeking the latest updates and insights on Xenon Pharmaceuticals stock.
Xenon Pharmaceuticals Inc. (Nasdaq: XENE) is a pioneering biopharmaceutical company headquartered in Vancouver, British Columbia. Focused on neurology, Xenon leverages its proprietary discovery platform, termed 'extreme genetics', to develop innovative medications. The company’s approach involves studying families with severe phenotypes to identify single-gene defects, which offer insights into human biology and serve as potential drug targets.
Xenon’s development pipeline targets a range of neurological disorders, particularly epilepsy and depression. The flagship product, XEN1101, is a potent, selective potassium channel opener currently in various phases of clinical trials for epilepsy and major depressive disorder (MDD). Xenon has ongoing Phase 3 trials for XEN1101 in focal onset seizures (X-TOLE2, X-TOLE3) and primary generalized tonic-clonic seizures (X-ACKT). The drug has shown promising efficacy in reducing seizures and improving quality of life in long-term extension studies.
Additionally, Xenon is exploring XEN1101's potential in treating MDD, with a Phase 3 program expected to begin in 2024. Recent interim data from the X-NOVA Phase 2 trial revealed significant improvements in depression symptoms, supporting further development for this indication. Xenon’s pre-clinical work includes investigations into Nav1.1 and Nav1.7 potentiators for various neurological conditions.
Key developments include a partnership with Neurocrine Biosciences to develop XEN901 (NBI-921352) for epilepsy. Xenon's financial stability, robust clinical pipeline, and strategic collaborations position it for continued growth and innovation in neurology-focused therapeutics.
Recent Achievements:
- Strong presence at AES 2023 with multiple presentations on XEN1101
- Presented new data from the Phase 2b X-TOLE trial demonstrating significant seizure freedom rates
- Expanded open-label extension study collecting over 500 patient years of data
- Announced positive topline results from X-NOVA Phase 2 trial for MDD
- Ongoing collaboration with Icahn School of Medicine for additional MDD studies
For more updates and detailed information, visit the official website.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) provided its financial results for 2020 and updates on its clinical trials. The company anticipates topline data from the Phase 2b ‘X-TOLE’ clinical trial for XEN1101 in adult focal epilepsy by Q3 2021, highlighting efficacy and safety. Total revenue rose to $32.2 million in 2020, driven by $26.8 million of deferred revenue. However, R&D expenses increased to $50.5 million. The net loss was reduced to $28.8 million compared to $41.6 million in 2019. Xenon has sufficient cash to fund operations into 2023, bolstered by partnerships.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) will report its 2020 financial results on March 1, 2021, after U.S. market close. A conference call and webcast will follow at 4:30 PM ET to discuss these results and provide a corporate update. Additionally, Xenon will participate in the SVB Leerink 10th Annual Global Healthcare Conference on February 24, 2021, at 10:00 AM ET, which will be webcast live.
Xenon is focused on developing innovative therapeutics for neurological disorders, particularly epilepsy.
Xenon Pharmaceuticals (XENE) presented promising pre-clinical and clinical data on XEN1101, a Kv7 potassium channel modulator, at ASENT 2021. The ongoing Phase 2b X-TOLE clinical trial shows XEN1101 is effective as adjunctive treatment for adult patients with focal epilepsy, with results expected in Q3 2021. New data suggest potential efficacy for mood disorders like depression and anhedonia. Initial results indicate XEN1101 may be well-tolerated, with positive pre-clinical evidence supporting its use in combinations with other medications.
Xenon Pharmaceuticals announces a leadership transition planned for June 2021, with Simon Pimstone stepping down as CEO to become Executive Chair, while Ian Mortimer will take over as CEO. The company anticipates key milestones in 2021, including topline data from the XEN1101 Phase 2b X-TOLE trial for adult focal epilepsy, expected in Q3 2021, and the initiation of the Phase 3 EPIK trial for XEN496 in pediatric KCNQ2-DEE. The press release highlights the company's commitment to developing innovative treatments for neurological disorders.
Xenon Pharmaceuticals announced promising interim data on XEN007 from a Phase 2 study for treating Childhood Absence Epilepsy (CAE). All three patients demonstrated over a 50% reduction in seizures, with two achieving over 80% reduction. The study is well tolerated with no serious adverse events reported. Future enrollment will focus solely on CAE, given these favorable results. Xenon continues to advance its pipeline, including XEN1101 and XEN496, with presentations scheduled at AES2020.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) announced that CEO Dr. Simon Pimstone will participate in key virtual investor conferences. These include:
- Guggenheim Healthcare 2nd Annual Neuro/Immunology Day on November 16, 2020.
- Stifel 2020 Virtual Healthcare Conference on November 17, 2020, at 4:40 pm ET.
- Jefferies Virtual London Healthcare Conference on November 19, 2020, at 9:40 am ET (2:40 pm GMT).
Details and webcasts will be available on the company website following the events.
Xenon Pharmaceuticals (Nasdaq:XENE) reported third quarter 2020 financial results, highlighting a total revenue of $6.6 million, up from $3.5 million in Q3 2019. Cash reserves stand at approximately $191 million, extending their cash runway into 2023. The company is progressing with its XEN1101 Phase 2b and XEN496 Phase 3 clinical trials, despite COVID-19 challenges. Additionally, Patrick Machado was appointed to the Board of Directors, bringing over 20 years of biotech experience. Topline data for the X-TOLE trial is now expected in Q3 2021.
Xenon Pharmaceuticals (Nasdaq:XENE) announced it will release its Q3 2020 financial and operating results after U.S. markets close on November 5, 2020. Management will host a conference call and live webcast at 4:30 PM ET to discuss results and provide a corporate update. Investors can participate by calling (855) 779-9075 or (631) 485-4866 for international access, using conference ID 8125409. The event will be accessible on Xenon’s website and available for replay for 30 days.
Xenon Pharmaceuticals announced a positive opinion from the European Medicines Agency's COMP for orphan medicinal product designation for XEN496, aimed at treating KCNQ2 DEE. The FDA has also granted Fast Track designation for XEN496, with plans to initiate a Phase 3 clinical trial in pediatric patients by year-end. The trial will evaluate the efficacy and safety of XEN496 in approximately 40 pediatric patients. This milestone underscores the seriousness of KCNQ2-DEE and validates Xenon's precision medicine approach.
The FDA has requested additional non-clinical data from Neurocrine Biosciences to support the dose justification for NBI-921352 in a Phase II trial for pediatric SCN8A-DEE patients. This request follows the granting of Rare Pediatric Disease Designation for NBI-921352, which targets a rare pediatric epilepsy. Neurocrine and Xenon Pharmaceuticals are collaborating on this project and aim to initiate the trial in 2021, while also advancing plans for adult focal epilepsy treatment.
FAQ
What is the current stock price of Xenon Pharmaceuticals (XENE)?
What is the market cap of Xenon Pharmaceuticals (XENE)?
What does Xenon Pharmaceuticals specialize in?
What is the focus of Xenon’s proprietary discovery platform?
What is XEN1101?
What are the recent achievements of Xenon Pharmaceuticals?
Who are Xenon’s strategic partners?
What are Xenon’s key products in the pipeline?
What is the status of the XEN1101 epilepsy trials?
How can I contact Xenon Pharmaceuticals for investor information?
Where is Xenon Pharmaceuticals headquartered?
What is the significance of Xenon’s pre-clinical work?
